Atopic dermatitis (AD) is a chronic relapsing inflammatory disease characterized by impairment of the skin barrier function and abnormalities in the innate and adaptive immune responses of the skin [1](#pde12786-bib-0001){ref-type="ref"}, [2](#pde12786-bib-0002){ref-type="ref"}.

Lower bacterial diversity in the skin microbiome was recently reported to be of major importance in AD pathogenesis [3](#pde12786-bib-0003){ref-type="ref"}. *Staphylococcus aureus* in particular has been shown to be involved in exacerbations of AD, with the density of *S. aureus* colonization in AD lesions correlating with the severity of dermatitis [4](#pde12786-bib-0004){ref-type="ref"}, [5](#pde12786-bib-0005){ref-type="ref"}.

Regardless of AD severity, restoration of skin barrier integrity is one of the main therapeutic goals achieved by using emollients, which are strongly recommended as first‐line agents [2](#pde12786-bib-0002){ref-type="ref"}, [6](#pde12786-bib-0006){ref-type="ref"}, [7](#pde12786-bib-0007){ref-type="ref"}, [8](#pde12786-bib-0008){ref-type="ref"}, [9](#pde12786-bib-0009){ref-type="ref"}. Although lipid‐containing emollients can act by forming an occlusive layer over skin, they may have other mechanisms of action [9](#pde12786-bib-0009){ref-type="ref"}.

To improve our knowledge of these mechanisms, we assessed the effects of a new emollient balm on AD clinical parameters (SCORing Atopic Dermatitis \[SCORAD\], xerosis, pruritus), skin barrier function (transepidermal water loss \[TEWL\] and loricrin, filaggrin, corneodesmosin, and involucrin expression), skin microflora biodiversity, and *S. aureus* and *Staphylococcus epidermidis* balance in children with mild AD.

Patients and Methods {#pde12786-sec-0006}
====================

This open, randomized controlled clinical study was conducted in three hospitals in Italy and Romania in accordance with the ethical principles of the Declaration of Helsinki, Good Clinical Practice guidelines (CPMP/ICH/135/95), and national regulations. Local independent ethics committees approved the protocol. Volunteers were included after their parents or guardians had provided written informed consent.

Patients {#pde12786-sec-0007}
--------

One‐ to 4‐year‐old children with mild AD (SCORAD 5--20) and mild to moderate xerosis on the selected measurement areas (SCORAD xerosis score of 1 or 2) not exhibiting AD flares at inclusion were enrolled. Exclusion criteria were use of topical corticosteroids within 7 days or systemic corticosteroids within 15 days before inclusion, history of allergy to study product components, immunodeficiency or chronic or acute diseases, treatment with a reintroduction diet or immunosuppressants in the month before inclusion, systemic antibiotics, topical or systemic antiinflammatory treatment or probiotics within 2 weeks before inclusion, topical immunosuppressants, antibiotics, antiseptics or antihistamines in the week before inclusion, or use of any emollient cream within 48 hours before inclusion. Breastfed children of mothers receiving immunosuppressants in the month before inclusion; systemic corticosteroids, antibiotics, or antiinflammatory agents or probiotics in the 2 weeks before inclusion; or antihistamines in the week before inclusion were excluded.

Treatments {#pde12786-sec-0008}
----------

The study product (Avene Xeracalm balm; Pierre Fabre Dermo Cosmétique, Boulogne, France) was an oil‐in‐water emulsion to be applied to the dry skin of the children\'s face and body after bathing twice a day for 28 days. The associated hygiene product (emollient cleansing gel; Trixera; Pierre Fabre Dermo, Boulogne, France) was indicated for dry and atopic skin and was used for bathing and then rinsed off once a day for 28 days.

Study Design {#pde12786-sec-0009}
------------

Children were randomized to receive the study product and the hygiene product (emollient group) or the hygiene product only (control group) and were followed for 28 days with visits at day 0 (D0, baseline) and after 15 (D15) and 28 days (D28). Clinical and barrier function parameters were assessed at each visit and microbiological diversity at D0 and D28.

Clinical Parameters {#pde12786-sec-0010}
-------------------

AD global severity was assessed using the SCORAD index, a validated clinical tool for assessing AD global severity [10](#pde12786-bib-0010){ref-type="ref"}, [11](#pde12786-bib-0011){ref-type="ref"}, [12](#pde12786-bib-0012){ref-type="ref"}. The intensity of xerosis and pruritus was measured over the whole body using the respective SCORAD‐derived scales (0 = absence, 3 = severe).

Barrier Function Parameters {#pde12786-sec-0011}
---------------------------

TEWL was assessed using an Aquaflux AF200 (Biox Systems, London, UK) on an area prone to AD flares.

RNA expression of involucrin, loricrin, filaggrin, and corneodesmosin was quantified using real‐time reverse transcription polymerase chain reaction (RT‐PCR) analysis. Skin samples were taken by scratching the skin using a sterile microabrasive tool (Vitry, France). Total RNA was isolated using an automated RNA purification kit (RNeasy mini QIAcube kit; Qiagen, Courtaboeuf, France) and complementary DNA (cDNA) was synthesized using a high‐capacity cDNA reverse transcription kit (Life Technologies, Saint‐Aubin, France), in accordance with the manufacturers\' instructions. DNA amplification was performed as described previously [13](#pde12786-bib-0013){ref-type="ref"} using primers and probes Hs00221623_m1 (corneodesmosin), Hs00856927_g1 (filaggrin), Hs00902520_m1 (involucrin), Hs01894962_s1 (loricrin), and RPLP0 (Hs99999902_m1) (Life Technologies). Results are expressed as fold change = 2^(−ΔΔCt)^.

Skin Microbiological Diversity {#pde12786-sec-0012}
------------------------------

Purification of DNA was performed using the QIAamp DNA Investigator Kit automated on the QIAcube apparatus (Qiagen) in accordance with the manufacturer\'s directions. The V1--V3 16S ribosomal RNA (rRNA) gene variable regions were amplified by PCR using 454 sequencing methods (Roche, Boulogne‐Billancourt, France), as described previously [14](#pde12786-bib-0014){ref-type="ref"}. Purified amplicon DNAs were sequenced on a 454 instrument using FLX titanium chemistry (GenoScreen, Lille, France) in accordance with the manufacturer\'s instructions. Sequence analysis was performed with GnS‐PIPE (Genosol, Dijon, France). The reads were assigned to operational taxonomic units using the SILVA database with USEARCH. Biodiversity was estimated by calculating the Shannon index (H′; accounts for abundance and evenness of species present in a community).

To quantify *S. aureus* and *S. epidermidis*, real‐time PCR was performed with absolute quantification analysis using a standard curve (ATCC 700699 for *S. aureus*, 12228 for *S. epidermidis*): *S. aureus* sodA: primers forward: GAGCATCAATCACTAGCGGA, reverse: ACCGCCATTATTACGGACTG, FAM‐probe: TGCTAACTTAGACAAGGTACCGG; *S. epidermidis* sodA: primers forward: TTTAGAAGCTAAATCAATCGAAGAAA, reverse: GGTGACCACCGCCATTATTA, FAM‐probe: TGCCATCTAATATTCAAACAGCTGT. Because sodA is present in a single copy number, the number of copies corresponds to the number of bacteria.

Statistical Analysis {#pde12786-sec-0013}
--------------------

Analysis of covariance was performed on changes from baseline using visit, site, and product as fixed factors and baseline as covariate. Results were considered significant at p \< 0.05.

Results {#pde12786-sec-0014}
=======

Flow of Subjects and Demographic Characteristics {#pde12786-sec-0015}
------------------------------------------------

Of the 55 children included, 1 was excluded from the full analysis set (FAS) population (all randomized subjects having received one or more applications of the study product) because of the absence of postbaseline values. The FAS was therefore composed of 54 children ages 2.5 ± 1.0 years (range 1--4 years) with mild AD (mean SCORAD 11.7 ± 3.1): 28 in the emollient group and 26 in the control group. There was no significant difference between groups at baseline for any of the parameters analyzed.

Effect of the Emollient Balm on Clinical Parameters {#pde12786-sec-0016}
---------------------------------------------------

The SCORAD was significantly lower in both groups at D15 and D28 than at baseline, with a significantly greater change in the emollient group than in the control group (36% vs 17%, p = 0.02, at D15; 48% vs 20%, p \< 0.001, at D28) (Table [1](#pde12786-tbl-0001){ref-type="table-wrap"}). Pruritus intensity was also significantly less in both groups at D15 and D28 than at baseline but more in the emollient group than in the control group at D28 (75% vs 36%, p = 0.06). Xerosis intensity was significantly lower in the emollient group than in the control group at D15 (p = 0.01) and D28 (p = 0.03) (Fig. [1](#pde12786-fig-0001){ref-type="fig"}).

###### 

Clinical Parameters Before (D0) and After 15 (D15) and 28 (D28) Days of Treatment with the Emollient or a Hygiene Product (Control) in the Full Analysis Set Population

                                                   D0            D15           Change at D15 from D0, %                        D28           Change at D28 from D0, %
  ------------------------------------------------ ------------- ------------- ----------------------------------------------- ------------- -----------------------------------------------
  SCORing Atopic Dermatitis                                                                                                                  
  Emollient                                        11.7 ± 3.1    7.5 ± 2.7     −36.1[†](#pde12786-note-0002){ref-type="fn"}    6.1 ± 2.4     −48.0[†](#pde12786-note-0002){ref-type="fn"}
  Control                                          10.2 ± 3.3    8.5 ± 5.0     −16.9[\*](#pde12786-note-0002){ref-type="fn"}   7.8 ± 5.8     −19.7[\*](#pde12786-note-0002){ref-type="fn"}
  p‐value[‡](#pde12786-note-0004){ref-type="fn"}   NS            0.02                                                          \<0.001       
  Pruritus intensity                                                                                                                         
  Emollient                                        1.67 ± 1.20   0.86 ± 1.11   −48.5[†](#pde12786-note-0002){ref-type="fn"}    0.43 ± 0.68   −74.6[†](#pde12786-note-0002){ref-type="fn"}
  Control                                          1.77 ± 1.52   1.02 ± 1.20   −42.5[\*](#pde12786-note-0002){ref-type="fn"}   1.01 ± 1.73   −35.9[\*](#pde12786-note-0002){ref-type="fn"}
  p‐value[‡](#pde12786-note-0004){ref-type="fn"}   NS            NS                                                            0.06          

Versus D0, \*p \< 0.01, †p \< 0.001.

‡ Intergroup comparison.

NS, not significant.
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![Effect of emollient on xerosis. Clinical assessment of xerosis at baseline and after 15 (D15) and 28 (D28) days of treatment. Data are expressed as the percentage of subjects with different degrees of severity of xerosis (\*p \< 0.05).](PDE-33-165-g001){#pde12786-fig-0001}

Effect of the Emollient Balm on Skin Barrier Function {#pde12786-sec-0017}
-----------------------------------------------------

TEWL values in the emollient group were 32% lower at D15 (p = 0.04) and 34% lower at D28 (p = 0.06) than at baseline, whereas they were unchanged in the control group, regardless of the duration of application (data not shown).

Of the four barrier‐specific genes studied, only involucrin was modified in the emollient group, with 37% lower expression (p = 0.001) at D28 than at baseline, whereas no change in expression was observed in the control group (Fig. [2](#pde12786-fig-0002){ref-type="fig"}). The intergroup difference was not significant (p = 0.06).

![Involucrin gene expression analysis after application of hygiene product and emollient for 28 days. Values are expressed as fold change from baseline (D0). Data are mean ± standard error of the mean (\*\*p \< 0.01 vs baseline).](PDE-33-165-g002){#pde12786-fig-0002}

Effect of the Emollient Balm on Skin Microflora Biodiversity and Balance Between *S. aureus* and *S. epidermidis* {#pde12786-sec-0018}
-----------------------------------------------------------------------------------------------------------------

At D0, *S. aureus* was found in 28% of the subjects in the emollient (8/28) and control groups (7/26) and *S. epidermidis* was detected in 100% of the subjects in the area studied. At D28, the number of *S. epidermidis* was not different in either of the two groups (Fig. [3](#pde12786-fig-0003){ref-type="fig"}A). In contrast, *S. aureus* was 6.5 times as great (p = 0.01) in the control group but was unchanged in the emollient group (Fig. [3](#pde12786-fig-0003){ref-type="fig"}B), with a significant between‐group difference at D28 (p = 0.049).

![Effect of emollient on the balance between *Staphylococcus aureus* and *Staphylococcus epidermidis*. Quantification of (**A**) *S. epidermidis* and (**B**) *S. aureus* using quantitative polymerase chain reaction and absolute quantification. Data are expressed as sodA gene copy number ± standard error of the mean. *S. aureus* copy values for inflammatory and xerotic areas are given as references for AD subjects with a SCORing Atopic Dermatitis score of 20 (\*p \< 0.05 vs baseline).](PDE-33-165-g003){#pde12786-fig-0003}

In terms of the distribution of skin bacterial communities (Fig. [4](#pde12786-fig-0004){ref-type="fig"}), the Shannon index (H′) remained stable in both groups at D28 from D0.

![Effect of treatments on skin microflora diversity. Genus proportion calculated from 16S ribosomal RNA pyrosequencing data associated with the Shannon index (diversity index) at baseline (D0) and after application of emollient or hygiene product for 28 days (D28).](PDE-33-165-g004){#pde12786-fig-0004}

Discussion {#pde12786-sec-0019}
==========

In this study, we demonstrated that daily use of emollient balm for 28 days significantly improved mild AD, with a greater decrease in all clinical parameters, SCORAD, xerosis, and pruritus than with a simple hygiene product. The emollient induced a decrease in TEWL and involucrin gene expression not observed in the control group. Most importantly, we showed that twice‐daily application of emollient balm in children with mild AD could protect the skin from *S*. *aureus* proliferation without affecting microflora biodiversity.

Although AD severity in our cohort was mild according to SCORAD [15](#pde12786-bib-0015){ref-type="ref"}, it improved significantly after 15 days of treatment, together with a decrease in TEWL, suggesting that the restoration of barrier function mediated the positive effect of the emollient on clinical status. This result is in line with the significant correlations observed previously between clinical scores, TEWL, and skin hydration in individuals with AD [16](#pde12786-bib-0016){ref-type="ref"}, [17](#pde12786-bib-0017){ref-type="ref"}, [18](#pde12786-bib-0018){ref-type="ref"}.

In addition to a decrease in TEWL, the restoration of skin barrier function induced by the emollient might also indicate a decrease in involucrin messenger RNA (mRNA) expression since no other protein involved in barrier function (filaggrin, loricrin, corneodesmosin) was affected. These results are consistent with the data of Grzanka et al [19](#pde12786-bib-0019){ref-type="ref"}, who observed overexpression of involucrin mRNA in lesional skin followed by a significant decrease after administration of pimecrolimus, a treatment shown to be effective in restoring the epidermal barrier, whereas filaggrin and loricrin gene expression was not modified.

Impairment of skin barrier function in individuals with AD is also associated with a greater susceptibility to *S. aureus* [2](#pde12786-bib-0002){ref-type="ref"}, [20](#pde12786-bib-0020){ref-type="ref"}, the main bacterial species found to be directly correlated with AD severity [5](#pde12786-bib-0005){ref-type="ref"}. In our study population, the low prevalence of *S. aureus* in xerotic areas (28% of patients before treatment in both groups) is consistent with the mild severity of their disease; it can reach up to 90% in inflammatory areas in patients with severe AD [5](#pde12786-bib-0005){ref-type="ref"}, [16](#pde12786-bib-0016){ref-type="ref"}. On the other hand, *S. aureus* levels were unchanged after emollient treatment, whereas they increased significantly in the control group. This suggests that the emollient may protect against an increase in *S. aureus* population by restoring barrier function and modulating involucrin, which is known to play an important role in *S. aureus* adhesion via a staphylococcal adhesin receptor [21](#pde12786-bib-0021){ref-type="ref"} and thus maintain the balance between *S. aureus* and *S. epidermidis*, which plays a major role in AD severity and flare frequency.

New insights into skin microbiome composition in individuals with AD have revealed that exacerbation of the disease is strongly associated with lower skin bacterial diversity [3](#pde12786-bib-0003){ref-type="ref"}. In our patients with mild AD, the Shannon index (H′ = 2.3) was intermediate between that observed after a flare in a similar population (H′ = 2) and that in healthy subjects (H′ = 3) and much higher than in patients with severe AD (H′ = 1) [3](#pde12786-bib-0003){ref-type="ref"}. This index did not change over the treatment period in either group, showing that skin bacterial diversity was maintained with both treatments. The fact that the Shannon index was not modified in the control group despite an increase in *S. aureus* density could be because the change in density was too small (222 vs 33 copies) and that this was statistically but not clinically significant. The magnitude of increase was much lower than in inflammatory or xerotic areas of patients with severe AD (Fig. 3B).

Because this study lasted only a month, we were unable to prove that our emollient can postpone flares by maintaining the balance between *S. aureus* and *S. epidermidis* and that an increase in the *S. aureus* population can predict disease worsening and flares. Furthermore, the absence of placebo is a limitation but may be explained by the difficulty of designing and developing placebos in cosmetic studies [22](#pde12786-bib-0022){ref-type="ref"}. To our knowledge, there are no data available on the evolution of the skin microbiome in mild AD in the absence of emollient treatment. It thus seemed interesting to compare the balance between *S. aureus* and *S. epidermis* over several weeks in children with mild AD who used the emollient daily with that of children with the same skin condition without any emollient treatment. Our results emphasized the role of the emollient in skin hydration and of microbiota balance for maintenance treatment in AD.

In our study, a pediatric population with mild AD was chosen specifically because it is the target of cosmetic emollients. Despite the mild nature of the condition, we demonstrated in a controlled randomized pilot study that an emollient balm is effective in improving AD severity, restoring skin barrier function, and maintaining a balance between *S. aureus* and *S. epidermis*. Further long‐term controlled studies are needed to evaluate the role of emollients in maintaining a diversified skin microflora and to establish whether an increase in *S. aureus* precedes AD flares.
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